Abstract 1082
Background
Older cancer patients are a vulnerable group of medication users. Pharmacist-led medication reviews may optimize treatment and thereby reduce the risk of harmful effects from medication use. This study aims to determine the prevalence and management of Potentially Inappropriate Medication use (PIM’s) and Potential Omissions in Medication (POM’s) in older cancer patients.
Methods
In this prospective observational study (hospital) pharmacists conducted medication reviews with older cancer patients (aged ≥65 years) treated with parenteral chemo and/or immunotherapy to determine the prevalence of PIM’s and POM’s. PIM’s and POM’s were identified using the Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP), the screening Tool to Alert doctors to the Right Treatment (START) and pharmacists’ expert opinion. Recommendations regarding PIM’s and POM’s were made to the patient’s oncologist/haematologist and follow-up was measured. Associations between covariates and the prevalence of PIM’s and POM’s were statistically analysed.
Results
117 (78%) of the 150 patients included (median age 72 years, 59% male, 68% solid tumours, mean number of medicines 11) had at least one PIM and/or PIM. In total 266 PIM’s and POM’s were identified, and these led to 195 (73%) follow-up actions (table). The number of medicines and Charlson Comorbidity Index score (as a measure of vulnerability) were both independently associated with having at least one PIM and/or POM (p = .031 and p = .002 respectively).Table:
1825P Identification and follow-up of PIM’s and POM’s
PIM’s and POM’s | |
---|---|
n (%) | |
PIM’s, total Using STOPP | 180 89 (49) |
Using expert opinion | 85 (47) |
Using both | 6 (3) |
POM’s, total Using START | 86 66 (77) |
Using expert opinion | 20 (23) |
Follow-up actions By oncologist/haematologist | 266 77 (29) |
By general practitioner | 118 (44) |
No follow-up action | 71 (27) |
Conclusions
PIM’s and POM’s are highly prevalent among older cancer patients. A pharmacist-led medication review using STOPP/START criteria and pharmacists’ expert opinion is an excellent way to identify these PIM’s and POM’s and to optimize patients’ medication use. The majority of recommendations made regarding PIM’s and POM’s leads to a follow-up action.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Deventer Teaching Hospital.
Funding
Has not received any funding.
Disclosure
F.G.A. Jansman: Advisory / Consultancy, 2016: Amgen; Advisory / Consultancy, 2016: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract